

## **D.1 - Exclusion of antiretroviral formulations from the WHO Model List of Essential Medicines and the WHO Model List of Essential Medicines for Children**

MSF agrees with the proposal from the WHO Department of Global HIV, Viral Hepatitis and Sexually Transmitted Infections Programmes (HHS) to delete from both the WHO Model List of Essential Medicines (EML) and the WHO Model List of Essential Medicines for Children (EMLc) the following antiretrovirals: efavirenz 200 mg scored tablet, ritonavir 400 mg/5 ml oral liquid, atazanavir 100 mg solid oral dosage form, lopinavir + ritonavir (LPV/r) 400 mg + 100 mg/5 ml oral liquid, raltegravir 100 mg chewable tablet and 400 mg tablet, zidovudine + lamivudine + nevirapine (300 mg + 150 mg + 200 mg) and to delete atazanavir 300 mg solid oral dosage form from the EML.

MSF also agrees with the proposal to delete zidovudine + lamivudine + nevirapine (60 mg + 30 mg + 50 mg) tablet from the EMLs, however we want to acknowledge the challenges of access to the currently recommended regimen with nevirapine (NVP) syrup for enhanced post-natal prophylaxis (ePNP) for prevention of mother to child transmission (PMTCT). Some countries have been using instead ¼ zidovudine + lamivudine + nevirapine (60 mg + 30 mg + 50 mg) tablet as a strategy to overcome lack of NVP syrup for ePNP.


MSF agrees with the proposal from the WHO HHS to delete from the EMLc only, the following antiretrovirals: lamivudine 150 mg tablet, abacavir 60 mg scored, dispersible tablet, ritonavir 100 mg oral powder sachet.

These deletions from the EMLs are proposed in accordance with the WHO most recent guidelines: the 2019 “Update of recommendations on first-and second-line antiretroviral regimens” and the 2021 “Optimal formulary and limited-use list for antiretroviral drugs for children”.

At the end of 2020, in collaboration with Health Authorities in 20 countries, MSF provided antiretroviral treatment for more than 192 000 people living with HIV/AIDS, including 16 800 patients on second-line antiretrovirals.

MSF urges the 23<sup>rd</sup> Expert Committee on the Selection and Use of Essential Medicines to delete the antiretrovirals listed in the proposal from WHO HHS, while taking into account the difficulties of accessing the recommended NVP syrup.

For Médecins Sans Frontières



Myriam Henkens, MD, MPH  
International Medical Coordinator